Phase 2 N=41 Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Study of Apremilast in Atopic or Contact Dermatitis
Atopic Dermatitis · Allergic Contact Dermatitis
Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
Phase 4 N=20 A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis
Hand Dermatitis
Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale
N/A N=148,166 Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
Atopic Dermatitis Eczema · Atopic Dermatitis · Eczema
Primary: Prescription Rates for Atopic Dermatitis Related Treatments: Emollients and Soap Substitutes — 76095 Participants
Phase 2 N=20 Effect of Benralizumab in Atopic Dermatitis
Dermatitis, Atopic · Dermatitis · Eczema
Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2
N/A N=9 Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis · Eczema
Primary: SCORAD Change Score — 33.34 Change Score
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019
Phase 2 N=16 Topical Ruxolitinib in Chronic Hand Dermatitis
Chronic Hand Dermatitis
Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants
Phase 3 N=65 8-Week Atopic Dermatitis (AD) Treatment Study
Atopic Dermatitis Eczema
Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05
Phase 2 N=60 Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change
Phase 4 N=30 A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
Seborrheic Dermatitis
Primary: Percent Change in ISGA (Investigator's Static Global Assessment) Score — 67.8 percent change
Phase 2 N=98 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch) — 7.3; 7.26; 4.27; 4.6 score on a scale — p== 0.249
Phase 3 N=683 Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
Atopic Dermatitis Eczema
Primary: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 — 28.9; 12.0 percentage of participants — p=<0.0001
Phase 3 N=51 A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin
Eczema
Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001
Phase 2 N=41 A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060
Atopic Dermatitis
Primary: Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 14 Full Analysis Set — -94; -100 Percent change — p=0.012
Phase 2 N=421 A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Achievement of EASI-50 — 38; 27; 25; 23 Participants
N/A N=42 Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis
Hand Dermatosis
Primary: Investigator Global Assessment — 1.0; 1.1 units on a scale
Phase 3 N=466 Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
Dermatitis · Eczema
Primary: Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score). — 131; 134; 37; 38 Participants
Phase 2 N=200 A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
N/A N=32 Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
Phase 3 N=326 Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
Atopic Dermatitis
Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…
Phase 2 N=66 Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
Stasis Dermatitis
Primary: Percent Change From Baseline in Total Sign Score (TSS) at Week 6: In-person Assessment — -18.07; -32.44 Percent change — p=0.0299
Phase 2 N=32 Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 4; 7 Participants
N/A N=121 A Clinical Investigation With Epaderm® Cream
Eczema · Psoriasis · Dry Skin; Eczema
Primary: Number of Participants With Improved Skin Moisturization — 114 Participants
Phase 2 N=119 Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
Atopic Dermatitis Eczema
Primary: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 — -43.5; -62.0 Percent change from baseline
Phase 1 N=28 A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis
Eczema · Atopic Dermatitis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs)as Assessed by CTCAE v4.0 — 11 Participants
Phase 3 N=654 Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Atopic Dermatitis Eczema
Primary: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 — 32.0; 15.2 percentage of participants — p=<0.0001
N/A N=32 Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Toxicities
Primary: Qualitative Data From Patients and Experts to Measure Anti-EGFR Therapy-specific Health-related Quality of Life (HRQL) — 2.70; 2.41; 2.70; 2.29 units on a scale